{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:37:03Z","timestamp":1786653423233,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Ophthalmol"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/0301-4738.171964","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T23:43:41Z","timestamp":1450309421000},"page":"832","source":"Crossref","is-referenced-by-count":6,"title":["Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab"],"prefix":"10.4103","volume":"63","author":[{"given":"DanielSanju","family":"Narayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Muecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0301-4738.171964-1","first-page":"246","volume-title":"Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration","author":"Boyer","year":"2007","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.171964-2","first-page":"1900","volume-title":"Age-related macular degeneration is the leading cause of blindness","author":"Bressler","year":"2004","journal-title":"JAMA"},{"key":"key-10.4103\/0301-4738.171964-3","first-page":"393","volume-title":"Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes","author":"Frank","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.171964-4","first-page":"154","volume-title":"Increased expression of angiogenic growth factors in age-related maculopathy","author":"Kliffen","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.171964-5","first-page":"1929","volume-title":"Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor","author":"Kvanta","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.171964-6","first-page":"855","volume-title":"Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes","author":"Lopez","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.171964-7","first-page":"3186","volume-title":"Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization","author":"Rakic","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.171964-8","first-page":"1837","volume-title":"Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: A report by the American Academy of Ophthalmology","author":"Ip","year":"2008","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.171964-9","first-page":"1419","volume-title":"Ranibizumab for neovascular age-related macular degeneration","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0301-4738.171964-10","first-page":"1432","volume-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0301-4738.171964-11","first-page":"239","volume-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.171964-12","first-page":"315","volume-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","author":"Abraham","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.171964-13","first-page":"1897","volume-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","author":"CATT","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0301-4738.171964-14","first-page":"3115","volume-title":"Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration","author":"Keane","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.171964-15","first-page":"723","volume-title":"Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration","author":"Forooghian","year":"2009","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.171964-16","first-page":"11393","volume-title":"VEGF-Trap: A VEGF blocker with potent antitumor effects","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/0301-4738.171964-17","first-page":"434","volume-title":"Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)","author":"Stewart","year":"2012","journal-title":"Retina"},{"key":"key-10.4103\/0301-4738.171964-18","first-page":"171","volume-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"key-10.4103\/0301-4738.171964-19","first-page":"222","volume-title":"Aflibercept for age-related macular degeneration: A game-changer or quiet addition?","author":"Browning","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.171964-20","first-page":"667","volume-title":"Predicted biological activity of intravitreal VEGF Trap","author":"Stewart","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.171964-21","first-page":"2537","volume-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.171964-22","first-page":"155","volume-title":"Switch to aflibercept in the treatment of neovascular AMD: One-year results in clinical practice","author":"Pinheiro-Costa","year":"2015","journal-title":"Ophthalmologica"},{"key":"key-10.4103\/0301-4738.171964-23","first-page":"638","volume-title":"Quantification of change in pigment epithelial detachment volume and morphology after transition to intravitreal aflibercept in eyes with recalcitrant neovascular AMD: 18-Month Results","author":"Kanesa-Thasan","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"key-10.4103\/0301-4738.171964-24","first-page":"560","volume-title":"Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment","author":"Gerding","year":"2015","journal-title":"Klin Monbl Augenheilkd"},{"key":"key-10.4103\/0301-4738.171964-25","first-page":"226","volume-title":"Aflibercept treatment for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy refractory to anti-vascular endothelial growth factor","author":"Moon","year":"2015","journal-title":"Korean J Ophthalmol"},{"key":"key-10.4103\/0301-4738.171964-26","doi-asserted-by":"crossref","unstructured":"Brown DM, Chen E, Mariani A, Major JC Jr.; SAVE Study Group. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 2013;120:349-54.","DOI":"10.1016\/j.ophtha.2012.08.008"},{"key":"key-10.4103\/0301-4738.171964-27","first-page":"1032","volume-title":"Aflibercept for exudative AMD with persistent fluid on ranibizumab and\/or bevacizumab","author":"Cho","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0301-4738.171964-28","first-page":"15","volume-title":"Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab","author":"Bakall","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0301-4738.171964-29","first-page":"1860","volume-title":"Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0301-4738.171964-30","first-page":"1599","volume-title":"Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy","author":"Golbaz","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key-10.4103\/0301-4738.171964-31","first-page":"1260","volume-title":"Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits","author":"Gaudreault","year":"2007","journal-title":"Retina"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:08Z","timestamp":1786649828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0301-4738.171964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015]]}},"alternative-id":["171964"],"URL":"https:\/\/doi.org\/10.4103\/0301-4738.171964","relation":{},"ISSN":["0301-4738"],"issn-type":[{"value":"0301-4738","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}